PTC Therapeutics officer proposes $12.3K share sale
Boulding's reported common-stock sales during the preceding three months span August 17 to October 6, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
PTC Therapeutics, Inc. (PTCT) is the issuer for a proposed sale by officer Mark Elliott Boulding of 192 common shares, with an aggregate market value of $12,338.84. Fidelity Brokerage Services LLC is listed as broker, and the approximate sale date is October 9, 2026, on Nasdaq. The shares were acquired from the issuer through a stock option exercise for cash on October 9, 2026.
Key Figures
Key Terms
Rule 144 regulatory
Stock Option Exercise financial
attorney-in-fact technical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What prior PTCT sales by Mark Elliott Boulding are reported?
AI-generated analysis. How Rhea-AI works. Not financial advice.